Combidex FDA Approval Status
Combidex (ferumoxtran-10) is a investigational functional molecular imaging agent intended for use in conjunction with magnetic resonance imaging (MRI) to aid in the differentiation of cancerous from non-cancerous lymph nodes.
In March 2005, Advanced Magnetics, Inc. announced the receipt of an Approvable Letter from the U.S. Food and Drug Administration (FDA) requesting additional data to demonstrate the efficacy of Combidex (ferumoxtran-10).
Development Timeline for Combidex
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.